No Data
CMB International: With continued policy efforts, Bullish on the rebound of China Meheco Group's valuation.
Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a high-elasticity Industry, is expected to outperform the market in 2025.
China Meheco Group Co., Ltd.'s (SHSE:600056) Share Price Is Matching Sentiment Around Its Earnings
Meheco Unit's Angina Tablets Passes Chinese Drug Regulator's Consistency Evaluation
Meheco Unit's Sepsis Drug Included in China's Centralized Procurement Bid
China Meheco Group (600056.SH): Sodium piperacillin for injection is expected to be selected for centralized procurement.
China Meheco Group (600056.SH) announced that on December 12, 2024, its subsidiary in Hainan...
Meheco Receives Nod for Influenza Drug's Registration
Investors One-year Losses Continue as China Meheco Group (SHSE:600056) Dips a Further 9.1% This Week, Earnings Continue to Decline
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
